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ABSTRACT
In recent years, measurement of the
intraepidermal nerve fiber (IENF) density has
gained relevance in the diagnostics of chronic
pruritus. This method allows the objectification
and quantification of a small-fiber neuropathy,
which may manifest clinically with pruritus,
pain or dysesthetic sensory symptoms, such as
burning, stinging and tingling sensations or
numbness. Upon suspicion of a small-fiber
neuropathy as a cause for chronic pruritus,
targeted diagnostic procedures are essential for
the early detection of the neuroanatomical
changes. After a punch biopsy of the lower leg,
the obtained tissue undergoes an
immunofluorescence staining process with a
primary antibody against the protein gene
product 9.5. The IENFs can thus be detected
and are quantified according to pre-determined
guidelines based on an international consensus.
In addition to morphological changes,
functional impairment of small-fibers can be
assessed using quantitative sensory testing by
assessing detection and pain thresholds of
various thermal and mechanic modalities. This
method, however, is time-consuming and
requires a specialized investigator, and thus it
is not routinely used in the diagnostic
investigation of chronic pruritus. Diagnosing a
small-fiber neuropathy underlying chronic
pruritus has therapeutic relevance. If possible,
the underlying cause of the neuropathy should
be treated. Alternatively, symptomatic therapy
options include topical (capsaicin) and systemic
(anticonvulsants and/or antidepressants)
agents. Chronification processes may lead to
refractory pruritus, and thus treatment should
be initiated as soon as possible. The aim of this
review is to present and discuss the
measurement of the IENF density as a
diagnostic tool and its role in the
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management of patients with chronic pruritus.
A brief case report is presented to better
illustrate the role of this diagnostic method in
the clinical setting.
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INTRODUCTION
It is estimated that neuropathic pruritus, i.e.
pruritus caused by disorders of the
somatosensory system, accounts for
approximately 8% of cases of chronic pruritus,
while other possible causes include
dermatological, systemic, psychogenic or
multifactorial conditions, or may arise from
unknown causes [1]. The assessment of the
intraepidermal nerve fiber density (IENFD)
allows the morphological quantification of the
unmyelinated C-fibers crossing the basement
membrane of the epidermis. This diagnostic
tool has gained interest in recent years in the
diagnostics of neuropathic pruritus, since, next
to central processes, a dysfunction of the small
unmyelinated C-fibers plays a central role in
neuropathic pruritus [2]. In addition to pure
itch, damage to these nerve fibers can lead to
positive and negative neurological symptoms
that are generally more pronounced distally.
Interestingly, different cutaneous C fiber
subgroups and mediators are responsible for
various subjective qualities of chronic pruritus
[3]. Mechano-insensitive C fibers (CMi fibers)
utilize H1 receptors to mediate
histamine-induced pruritus through the ion
channel TRPV1 (transient receptor potential
channel V1) and phospholipase-b3 generating
a more pure itching, while mechano- and
heat-sensitive (CMH) C fibers mediate pruritus,
burning and thermal pain through the
activation of TRPV1 receptors [4]. The aim of
this review is to present the methodological
aspects of the quantification of IENFD, as well as
its diagnostic and therapeutic relevance for the
clinical practice. Additionally, a brief case report
is presented to demonstrate the role of this
diagnostic tool in the management of patients
with chronic neuropathic pruritus.
When to Assess the Intraepidermal Nerve
Fiber Density?
A reduced IENFD can be found in small-fiber
neuropathy of different origins, with pruritus as
the leading symptom. This reinforces the
pathophysiological concept that the genesis of
pruritus originates from unmyelinated nerve
endings in the epidermis and at the
dermoepidermal junction [2].
A detailed medical history is essential for the
diagnosis and further differentiation of
neuropathic pruritus. In neuropathic pruritus,
pathological processes causing itch may arise
from different levels of the somatosensory
system from the periphery to conditions of the
central nervous system [5], leading to a multitude
of possible clinical presentations. Depending on
the pathophysiological mechanisms, patients
may present a localized (e.g., in compression
syndromes such as brachioradial pruritus and
burning mouth syndrome) or generalized (e.g.,
in a generalized small-fiber neuropathy) pruritic
condition [6, 7]. Typical for neuropathic pruritus
is the report of sensory symptoms such as
burning, itching, stinging and even pain by the
affected patients. Additionally, the application
of ice packs or cold water often relieves the
itching, while warmth may worsen the
symptoms [2].
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Comorbidities associated with small-fiber
neuropathy should be thoroughly assessed,
especially its chronological association with
the onset of pruritus. Metabolic diseases often
induce small fiber neuropathy, for which
diabetes mellitus represents the most common
cause. Pruritus arising from diabetes mellitus
typically begins at the feet and lower legs or at
the torso [8]. Adjusting the postprandial glucose
levels generally provide relief from the pruritus
[9]. Other commonly associated diseases
include neurological syndromes. Compression
syndromes, such as brachioradial pruritus
(compression of the root ganglia or spinal
nerve C3–C6) and notalgia paresthetica
(compression of the dorsal rami Th2–Th6) are
associated with a reduced IENFD and thus to
localized pruritus in the affected dermatomes.
Other localized neuropathic syndromes leading
to small-fiber neuropathy and pruritus include
postherpetic neuralgia, vulvodynia or burning
mouth syndrome [6]. Moreover, skin diseases
have been linked to an impairment of
small-fibers. In sensitive skin, a condition in
which paraesthesias occur in apparently normal
skin mostly at the face, a reduced IENFD could
be demonstrated [10] and thus a neuropathic
involvement is speculated [11]. Prurigo
nodularis, in which itching hyperkeratotic
nodules develop due to chronic scratching, is
associated with a reduced IENFD regardless of
the underlying pruritic disease [12].
Interestingly, with improvement of the
prurigo condition, the IENFD may normalize
[13].
Many other diseases are associated with
small-fiber neuropathy without, however,
necessarily causing itch. These include
metabolic (e.g., vitamin B12 deficiency),
neurological (e.g., inflammatory demyelinating
diseases) immunological (e.g., rheumatoid
arthritis, lupus erythematodes, M. Sjo¨gren),
infectious (e.g., hepatitis C, HIV),
paraneoplastic and drug-induced (e.g.,
antibiotics, antiretroviral drugs, alcohol)
conditions [2, 14].
When the detailed clinical history provides
hints of a small-fiber neuropathy as the cause
for pruritus, the measurement of IENFD is the
gold standard for the objectification and
quantification of the neuropathy [15].
How to Assess the Intraepidermal Nerve
Fiber Density?
Punch Biopsy
The measurement of the IENFD is a
well-established standardized laboratory
method to quantify small-fiber neuropathy.
European guidelines addressing this issue
provide detailed recommendations for the
biopsy site, methodology of the employed
immunohistochemical staining and
quantification of the IENFD [16, 17]. The
diagnostics are carried out with a
3-mm-diameter punch biopsy. The anatomical
localization of the biopsy site is of paramount
importance for the measurement of the IENFD
[15]. Age and gender-adapted standard value
tables with cutoff values for the diagnosis of
small fiber neuropathy are, until now, only
available for the lower leg [15, 18]. As a result of
this, the punch biopsy to assess IENFD is usually
performed at the standardized location in the
distal lower leg (10 cm above the lateral
malleolus) [17]. For skin biopsies from other
parts of the body, the guidelines recommend
conducting a biopsy of a similar, unaffected site
in order to compare the results of the affected to
the unaffected area [17]. A biopsy can be taken
from either the right or the left distal lower leg,
as this does not influence the IENFD [19]. An
additional biopsy from the lateral proximal
thigh (20 cm below the anterior superior iliac
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spine) can provide information on the proximal
distribution of the neuropathy [17].
Laboratory Work-Up
The skin probe obtained from the punch biopsy
is immediately fixed in paraformaldehyde and is
transported to the laboratory. Here,
immunohistochemical staining for discerning
intraepidermal nerve fibers is carried out. An
immunohistochemical or immunofluorescence
staining with a primary antibody against the
axonal marker protein gene product 9.5 (PGP
9.5) is the most commonly used method
[16, 17], for which standard values have been
established for the distal lower leg [15].
Counting Method
Precise instructions on how to quantify the
IENFD have been established in an
international consensus. Per tissue samples,
three sections in high magnification
(9200–400) are considered. Only single
intraepidermal nerve fibers that cross the
dermoepidermal junction are taken into
account while secondary branching or
fragments are not counted. The IENFD is then
determined by dividing the number of
intraepidermal nerve fibers crossing the
dermoepidermal junction to the length of the
dermoepidermal junction (Fig. 1) [16, 17].
Normative Values
Age- and gender-specific variation exists in the
IENFD. While the IENFD seems to decline with
age, women show higher IENFD compared to
men [17]. These aspects have been taken into
consideration in the establishment of standard
normative values. Cutoff values are thus
stratified according to age per decade and
gender, displaying 5% percentiles of the
IENFD for each group (Table 1) [15, 18].
The localization of the obtained tissue also
influences the intraepidermal nerve fiber
density. Currently normative values are only
Table 1 Normative values for the intraepidermal nerve
ﬁber density assessed at the distal lower leg (10 cm above
the lateral malleolus) according to [14]






Fig. 1 PGP 9.5 intraepidermal nerve ﬁbers. a Example of
PGP 9.5 intraepidermal nerve ﬁbers (red arrows). b Only
single intraepidermal nerve ﬁbers crossing the dermoepi-
dermal junction (arrowhead) are taken into account.
Secondary branching (asterisks) or c fragments (white
arrow) are not counted. Magniﬁcation: 9200, scale bar
100 lm in (a); 9400, scale bar 100 lm in (b, c). PGP 9.5
protein gene product 9.5
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available for the distal lower leg. However, a
study is underway characterizing the density of
intraepidermal nerve fibers in various body
locations, both in healthy control subjects and
in patients with atopic eczema and neuropathic
pruritus (study ID: DRKS00010520).
Another aspect to consider is the laboratory
method used to identify the intraepidermal
nerve fibers, since the IENFD can vary
depending on the utilized staining method.
The immunofluorescence method tends to
display higher IENFD values compared to the
bright field staining method [20]. Normative
value table have been developed for both
methods [15, 18].
Altered Neuroanatomy in Pruritic Diseases
Neuroanatomical changes have been reported
for different pruritic diseases, including atopic
dermatitis or prurigo nodularis, in which
dermal hyperinnervation occurs. These
alterations in neuroanatomy are associated
with functional impairment and with itch
induction. An imbalance of nerve elongation
factors (e.g., nerve growth factor) and nerve
repulsion factors (e.g., semaphorin 3A) is
thought to lead to the development of
neuroanatomical changes [21]. Although
hyperinnervation of dermal nerves has been
found in chronic pruritus diseases and prurigo
nodularis, the number of intraepidermal nerve
fibers crossing the basal membrane are reduced
compared to healthy individuals [22]. Here,
scratching behavior leading to a rarefication of
epidermal nerves may play a role [12].
Importantly, different methods analyzing
changes of intraepidermal nerve fibers have
been developed. The method quantifying the
intraepidermal nerve fiber density described
above differs from other methods, in which
enhanced intraepidermal sprouting is assessed.
Other Diagnostic Tools
Other methods exist to quantify sensory
dysfunction of cutaneous nerves; however,
they find only limited use in the assessment of
chronic pruritus. Quantitative sensory testing
(QST) allows the functional examination of the
peripheral nerve fibers and is thus
complementary to morphological methods
[23]. This non-invasive method consists of a
battery of tests assessing the subjective
somatosensory response to graded stimuli of
different modalities [24–26], allowing the
examination of functional impairment of
peripheral and central nerve tracts, as well as
central modulation mechanisms, especially
central sensitization [23]. For the study of
pruritic conditions, dysfunction of
unmyelinated C-fibers and thinly myelinated
Ad-fibers are of special interest. C-fibers are
activated by non-noxious heat stimulation as
well as by noxious cold and heat, while Ad-fibers
are activated by pinprick stimulation, noxious
heat and non-noxious cold stimulation. At
peripheral level, activation of unencapsulated
receptors occurs and signals are centrally
transmitted by the anterolateral spinothalamic
tract to higher centers [25, 26]. The German
Research Network on Neuropathic Pain has
established QST as a viable and standardized
protocol [23] that is now well established for
adults and with modifications for children [27].
Recently, QST was officially recommended by
the Neuropathic Pain Special Interest Group of
the International Association for the Study of
Pain both in research as well as in the clinical
evaluation of peripheral and central
neuropathies [24]. Notably, QST should not be
used as a stand-alone test for the diagnosis of
neuropathic pain.
Other functional methods assessing the
function of C- and Ad-fibers include
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somatosensory evoked potentials, in which
nerve transmission dysfunctions from
peripheral to central levels of the
somatosensory system can be detected [28], as
well as other diagnostic tools used mainly for
research purposes, such as laser-evoked
potentials, microneurography and the
neurometer. On the other hand, nerve
conduction studies, in which the function of
large myelinated Aa and Ab fibers is assessed
[29], are routinely used in neurology
departments. Although this method is not
usually used in the assessment of chronic
pruritus, nerve conduction studies may be
useful in the characterization of compression
syndromes, such as brachioradial pruritus [30]
or lumbosacral radiculopathy causing
anogenital pruritus [31]. This method is,
however, unable to detect a small-fiber
neuropathy, which is often associated with
compression syndromes inducing pruritus but
can be nicely combined with QST to give a
comprehensive functional overview.
In addition to the determination of IENFD,
another morphological method has been
developed in recent years. Corneal confocal
microscopy enables the study of morphological
changes in Ad and C fibers belonging to the
subbasal nerve plexus between the basal
epithelium and Bowman’s membrane [32–34].
Using a microscope connected to a retina
tomograph, the density of the nerve fibers
(nerve fibers/mm2) [35, 36] as well as the
length and branching are measured in order to
assess a possible small-fiber neuropathy.
Although this method is expensive and only
available in few centers, it has shown to be
useful in the early diagnosis of diabetic
neuropathy [37].
Therapeutic Relevance of the Cutaneous
IENFD
An IENFD below the 5% percentile of the
corresponding gender and age argues for a
small fiber neuropathy. However, this finding
alone is not sufficient for the diagnosis of a
small-fiber neuropathy. A suitable clinical
history is essential for the diagnosis of a
small-fiber neuropathy underlying chronic
pruritus. Importantly, chronic scratching
behavior, for instance, can also cause a
reduced IENFD [12] and should be taken into
consideration when interpreting the results of
this investigation.
An early start of the treatment is essential to
its effectiveness. It is recommended that the
attending physician initiates a directed
treatment against a suspected small-fiber
neuropathy, even before confirmation with
objective diagnostic methods such as the
measurement of the IENFD. If the cause of the
neuropathy is known, treatment of the
underlying condition is the most effective
measure. It is important to emphasize that
determination of the etiology of small fiber
neuropathy cannot be drawn based on the
morphological assessment of the IEFND [17]. If
it is not possible to identify and treat the
underlying cause, the European as well as the
German guidelines recommend a symptomatic
approach. The application of capsaicin cream in
rising concentrations, or, alternatively, a
capsaicin 8% patch, is the first-line treatment
for localized pruritus [38, 39], as was the case in
the brief case report presented in Fig. 2.
Capsaicin acts by destroying superficial
sensory nerves, depleting them from
neuropeptides and finds application in various
conditions, in which localized neurogenic
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pruritus or pain is present [40]. This treatment
may be repeated every 3 months, if necessary. If
the topical treatment does not lead to an
improvement of the symptom or in case of
generalized pruritus, the systemic
administration of anticonvulsants (e.g.,
gabapentin and pregabalin) should be
considered. These may be combined with
antidepressants such as paroxetine,
mirtazapine or amitriptyline, if additional
therapeutic effect is needed [38, 39].
CONCLUSION
Chronic pruritus may arise from a dysfunction of
small nerve fibers. In combination with a detailed
medical history, the determination of the
intraepidermal nerve fiber density in punch
biopsies is a simple well-established method to
detect a small-fiberneuropathy. An earlydiagnosis
of aneuropathyas theunderlying causeofpruritus
is essential for the treatment success. Current
guidelines recommend the treatment of the
underlying cause or, if not possible, the
application of topical capsaicin or the systemic
use of anticonvulsants or antidepressants.
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Fig. 2 Brief case report: application of an 8% capsaicin
patch. To better illustrate the role of the measurement of
the intraepidermal nerve ﬁber density in the management
of neuropathic pruritus, we present a brief case report.
Informed consent was obtained from the patient for being
included in the study. Medical history: A 45-year-old
female presented with localized pruritus at the upper back
between the scapulae. In addition to itch, the patient
reported a tingling and stinging sensation. These sensory
symptoms were of moderate intensity (5–6/10 in the
visual analogue scale), but could become very intense
during attacks (up to 9/10 in the visual analogue scale).
Skin status: Upon examination of the skin, discrete
erythematous lesions, likely due to scrubbing and scratch-
ing, could be observed in an otherwise normal skin. The
dermographism was white. Intraepidermal nerve ﬁber
density: Skin biopsies were taken at the back both in a
lesional and a non-lesional area: lesional skin probe:
2.41 ﬁbers/mm (strongly reduced IENFD) and non-le-
sional skin probe: 14.30 ﬁbers/mm (normal IENFD).
Diagnose: Notalgia paraesthetica. Previous therapies: A
treatment with antihistamines did not alleviate the
symptoms. The patient did not tolerate pregabalin due
to nausea and dizziness. Gabapentin (up to 900 mg/day) as
well as paroxetine (20 mg/day) showed no effect. Proposed
treatment: Due to the localized sensory symptoms, an 8%
capsaicin patch was applied in the affected area. The skin
condition of the affected area is shown before (a) and after
(b) application of the patch. A long-lasting itch relief is
expected with this treatment. However, the application of
the capsaicin patch may be repeated every 3 months or at
longer intervals, if needed. Additionally, a prescription for
a capsaicin cream in rising concentrations (0.025, 0.05 and
0.075%) was given to the patient to be used in case of itch
recurrence
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